Please use this identifier to cite or link to this item:
Title: Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.
Austin Authors: van der Veen, Sterre;Zutt, Rodi;Klein, Christine;Marras, Connie;Berkovic, Samuel F ;Caviness, John N;Shibasaki, Hiroshi;de Koning, Tom J;Tijssen, Marina A J
Affiliation: Department of Neurology, University Groningen, University Medical Center Groningen, Groningen, Netherlands
Department of Neurology, Haga Teaching Hospital, The Hague, The Netherlands
Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Neurology, University Groningen, University Medical Center Groningen, Groningen, Netherlands
Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
Kyoto University Graduate School of Medicine, Kyoto, Japan
Department of Neurology, University Groningen, University Medical Center Groningen, Groningen, Netherlands
Issue Date: Nov-2019 2019-10-04
Publication information: Movement disorders : official journal of the Movement Disorder Society 2019; 34(11): 1602-1613
Abstract: Genetically determined myoclonus disorders are a result of a large number of genes. They have wide clinical variation and no systematic nomenclature. With next-generation sequencing, genetic diagnostics require stringent criteria to associate genes and phenotype. To improve (future) classification and recognition of genetically determined movement disorders, the Movement Disorder Society Task Force for Nomenclature of Genetic Movement Disorders (2012) advocates and renews the naming system of locus symbols. Here, we propose a nomenclature for myoclonus syndromes and related disorders with myoclonic jerks (hyperekplexia and myoclonic epileptic encephalopathies) to guide clinicians in their diagnostic approach to patients with these disorders. Sixty-seven genes were included in the nomenclature. They were divided into 3 subgroups: prominent myoclonus syndromes, 35 genes; prominent myoclonus syndromes combined with another prominent movement disorder, 9 genes; disorders that present usually with other phenotypes but can manifest as a prominent myoclonus syndrome, 23 genes. An additional movement disorder is seen in nearly all myoclonus syndromes: ataxia (n = 41), ataxia and dystonia (n = 6), and dystonia (n = 5). However, no additional movement disorders were seen in related disorders. Cognitive decline and epilepsy are present in the vast majority. The anatomical origin of myoclonus is known in 64% of genetic disorders: cortical (n = 34), noncortical areas (n = 8), and both (n = 1). Cortical myoclonus is commonly seen in association with ataxia, and noncortical myoclonus is often seen with myoclonus-dystonia. This new nomenclature of myoclonus will guide diagnostic testing and phenotype classification. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
DOI: 10.1002/mds.27828
ORCID: 0000-0001-5783-571X
PubMed URL: 31584223
Type: Journal Article
Subjects: genetics
myoclonic epilepsy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.